Whether in vivo gene therapy products or in vitro gene-modified cell therapy products, the risk of gene insertion and mutation of integration in the gene modification safety evaluation are all key contents of concern. With the development of high-throughput sequencing and bioinformatics analysis technology, integrated site detection and analysis have been able to provide important information for understanding and judging risk. However, the safety prediction has not been achieved ideally. One of the core challenges is the methodological development of integration sites detection. On the one hand, it is the technical limitation of the assays, on the other hand, there is no public technical standard for the assays. In this paper, the commercial integration site detection technologies in safety evaluation of cell and gene therapy products are introduced. The challenges and future solutions are also discussed.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |